AtriCure, Inc.
NASDAQ:ATRCMedical - Instruments & Supplies
+$0.96 today
- Market cap
- $2.82B
- Beta
- 1.26
- P/E (TTM)
- -295.5
- EPS (TTM)
- -$0.10
Volume 0.60M
Average 0.77M
ATRC Net Income
Bottom-line profit, the starting point for calculating cash from operations.
AtriCure, Inc.NASDAQ: ATRC
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income turns positive
Q2 FY2026 net income was $8.96M, compared with -$6.19M a year earlier. Trailing-twelve-month net income was $10.55M. Over 3 fiscal years it compounded at -37.3% a year.
Context
- Net income amounted to 2.1% of revenue in FY2025, down 7.5 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 8 analysts of $9.91M (+186.6%) for the fiscal year ending Dec 2026, a step up from the -74.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $8.96M+8191.7% QoQ
- Last fiscal yearDec 2025
- -$11.45M-74.4% YoY
- LTMJun 2026
- $10.55M+129.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +244.7% | +930.2% | +685.5 pp |
| 1 year | -74.4% | +186.6% | +261.0 pp |
| 3-year CAGR | -37.3% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (11.45M) USD
- Year-over-year change
- +74.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.45M) | +74.4% |
| FY2024 | 2024-12-31 | (44.7M) | -46.8% |
| FY2023 | 2023-12-31 | (30.44M) | +34.5% |
| FY2022 | 2022-12-31 | (46.47M) | -192.6% |
| FY2021 | 2021-12-31 | 50.2M | — |
Net Income vs competitors
How ATRC compares with its peers on the latest reported figures
- ATRC's LTM Jun 2026 net income of $10.55M is the smallest of the 5 companies compared; the peer median is $2.34B.
- Its year-over-year change of +129.0% is the 2nd highest of 5, against a peer median of +23.6%.
- Net income amounts to 1.9% of revenue for ATRC, versus a peer median of 14.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $5.27B | +12.7% | +8.5% | 14.0% | |
| LTM Jun 2026 | $3.67B | +34.6% | +60.6% | 17.5% | |
| LTM Jun 2026 | $1B | -75.8% | -11.1% | 15.4% | |
| LTM Sep 2026 | $196.07M | +190.2% | +41.2% | 13.0% | |
| LTM Jun 2026 | $10.55M | +129.0% | -37.3% | 1.9% | |
| Peer median (excluding ATRC) | $2.34B | +23.6% | +24.8% | 14.7% | |
Competitors are the stored peer set for ATRC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 50.2M | (46.47M) | (30.44M) | (44.7M) | (11.45M) |
| Depreciation & Amortization | 10.44M | 11.71M | 14.81M | 18.73M | 20.53M |
| Deferred Income Tax | 84.78M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 28.08M | 28.77M | 35.73M | 40.41M | 44.69M |
| Change in Working Capital | (4.85M) | (18.88M) | (18.24M) | (18.36M) | (4.29M) |
| Accounts Receivables | (10.09M) | (8.99M) | (9.87M) | (8.3M) | (5.61M) |
| Inventory | (4.27M) | (7.31M) | (21.83M) | (7.74M) | (2.26M) |
| Accounts Payables | 4.71M | 2.68M | 6.18M | (1.53M) | (960K) |
| Other Working Capital | 4.81M | (5.26M) | 7.29M | (786K) | 4.54M |
| Other Non-Cash Items | (182.43M) | 2.72M | 2.62M | 16.12M | 7.85M |
| Operating Cash Flow | (13.78M) | (22.14M) | 4.48M | 12.2M | 57.33M |
| Capital Expenditures | (9.75M) | (16.88M) | (42M) | (23.46M) | (9.05M) |
| Acquisitions (Net) | (33.26M) | (44.01M) | 0 | 0 | 0 |
| Purchases of Investments | (173.11M) | (24.64M) | 0 | 0 | 0 |
| Sales of Investments | 206.36M | 85.52M | 63.82M | 0 | 0 |
| Other Investing Activities | 33.26M | 44.01M | (30M) | 41.69M | (5.5M) |
| Investing Cash Flow | 23.5M | 44.01M | 21.82M | 30.23M | (14.55M) |
| Debt Repayment | (816K) | (899K) | (992K) | (1.67M) | 5.05M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 7.29M |
| Common Stock Repurchased | (18.01M) | (12.2M) | (6.56M) | (6.95M) | (11.16M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 11.19M | 6.04M | 7.52M | 5.02M | 0 |
| Financing Cash Flow | (7.64M) | (7.06M) | (32K) | (3.6M) | 1.18M |
| Effect of Forex Changes | (372K) | (361K) | (58K) | (424K) | 747K |
| Net Change in Cash | 1.71M | 14.45M | 26.21M | 38.41M | 44.71M |
| Free Cash Flow | (23.53M) | (39.02M) | (37.51M) | (11.26M) | 48.28M |
AtriCure, Inc.
NASDAQ:ATRC
Intrinsic Alpha fair value
Locked
Current Price
$55.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.